Morning Read: Shkreli to take the 5th, Practice Fusion cuts 25 percent of workforce
Also, pharma to sit out Super Bowl ad rush and another insurer blames Obamacare for financial losses.
Also, pharma to sit out Super Bowl ad rush and another insurer blames Obamacare for financial losses.
Martin Shkreli Shkreli talks about cocaine in a new video railing against Wu Tang Clan member Ghostface Killah. Perhaps he should be talking about clozapine instead.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Martin Shkreli won't violate the terms of his bail when he travels to Washington to appear before a congressional committee on drug pricing, the U.S. DOJ writes.
Oh, and he may just burn that Wu Tang clan album.
Martin Shkreli won't talk drug prices at his forthcoming Congressional hearing, because Turing Pharmaceuticals is under an FTC antitrust probe.
Plus, end-of-life care is said to be far better outside hospitals, Meaningful Use may morph into something that heralds the age of "precision reimbursement" and GSK discusses a medtech JV with Qualcomm.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Along with Turing Pharmaceuticals, of which Martin Shkreli was formerly CEO, Valeant Pharmaceuticals will be investigated by Congress on January 26, Bloomberg reports.
Also, a look at concussion statistics and Polaris Health Directions will be providing MD Anderson Cancer Center with an Apple Watch medical app for a pilot study for breast Cancer patients.
Who would've realized this was just the beginning?
Up next: Digital health ditties? Biotech ballads? Payer/provider paeans?
Also, the ethical complications of drug pricing continue and UV robots might be the solution to killing germs in hospitals.
Also, Novartis outlines a new future in drug pricing and get a deep drive into both Google Capital and GE Healthcare.
Also, FDA launches a precision medicine platform, and we take a look at digital investment trends.
Ron Tilles, the chairman of the board for Turing Pharmaceuticals, has stepped up to replace Martin Shkreli as CEO.
The Shkreli affair, along with shenanigans from Valeant, have awakened serious journalists, who have started to look into drug pricing more broadly.